Epidural Steroid Injections for Spinal Pain
UnitedHealthcare Commercial and Individual Exchange Medical Policy
Proprietary Information of UnitedHealthcare. Copyright 2024 United HealthCare Services, Inc.
Eighteen randomized controlled trials met the inclusion criteria. Eleven randomized controlled trials dealt with various
aspects of transforaminal injections for radicular pain due to disc herniation and show Level 1 evidence supporting the use
of transforaminal injections for this condition. A meta-analysis showed that at both 3 and 6 months, there was highly
statistically significant improvement in both pain and function with both particulate and nonparticulate steroids. For
radicular pain from central stenosis there is one moderate quality study, with Level IV evidence. For radicular pain caused
by failed back surgery syndrome there is one moderate quality study, with Level IV evidence. For radicular pain from
foraminal stenosis and for axial pain there is Level V evidence, opinion-based/consensus, supporting the use of
transforaminal injections. The authors concluded that Level I evidence indicates transforaminal injections are generally
safe but have been associated with major neurological complications related to spinal cord infarction. Due to concern over
the role of particulate steroids, multiple other injectates have been evaluated, including nonparticulate steroids, tumor
necrosis factor alpha (TNF-a) inhibitors, and local anesthetics without steroids, and none have been proven superior. This
review is limited by the paucity of literature for some indications.
Verheijen et al. (2021) conducted a systematic review and meta-analysis comparing epidural steroid injections (ESIs) with
placebo injections in sciatica patients. The review included a total of 17 out of 732 reports: epidural placebo (n = 13), non-
epidural placebo (n = 2), and both placebo groups (n = 2). The primary outcome measures were pooled using a random-
effects model for 6-week, 3-month, and 6-month follow-up. Secondary outcomes were described qualitatively. Results
showed that ESI was superior compared to epidural placebo at 6 weeks (−8.6 [−13.4; −3.9]) and 3 months (−5.2 [−10.1;
−0.2]) for leg pain and at 6 weeks for functional status (−4.1 [−6.5; −1.6]), though the minimally clinical important
difference (MCID) was not met. There was no difference in ESI and placebo for back pain, except for non-epidural
placebo at 3 months (6.9 [1.3; 12.5]). Proportions of treatment success were not different. ESI reduced analgesic intake in
some studies and complication rates were low. Of the 17 trials, five were considered low risk of bias, two raised some
concerns, and 10 studies were considered high-risk. One serious adverse event was documented (retroperitoneal
hematoma after ESI) and several minor complications related to needle placement and corticosteroid were noted.
Limitations of the review include a low quality of evidence and limited number of comparison studies. The authors
concluded that ESIs compared to placebo is considered safe and effective treatment for short-term pain management,
however, at three and six months, no proven additional value of ESI compared to placebo was noted.
In a 2020 meta- analysis of randomized controlled trials, Yang et al. compared the clinical effectiveness of epidural steroid
injections (ESI) versus conservative treatments for patients with lumbosacral radicular pain. A search was conducted on
relevant studies published between 2000 and January 10, 2019 and randomized controlled trials directly comparing the
efficacy of ESI with conservative treatment were selected. Primary Outcomes included pain relief, functional improvement
using The Oswetry Disability Index, or successful events. 6 randomized controlled trials (249 patients with ESI and 241
patients with conservative treatment) were identified and included in this meta-analysis. The results showed that ESI was
beneficial for pain relief at short-term (1-3 months) and intermediate-term (3-6 months) when compared with conservative
treatment, but this effect was not maintained at long-term (6 months to one year) follow-up. In terms of functional
improvement, the overall outcome of meta-analysis showed that ESI did not have any advantage over conservative
treatment at short-term and intermediate-term follow-up. Successful event rates were significantly higher in patients who
received ESI than in patients who received conservative treatment. There were no statistically significant differences in
functional improvement after ESI and conservative treatment at short-term and intermediate-term follow-up. The authors
concluded that the use of ESI is more effective for alleviating lumbosacral radicular pain than conservative treatments in
terms of short-term and intermediate term. Patients also reported more successful outcomes after receiving ESI when
compared to conservative treatment. However, this effect was not maintained at long-term follow-up. The limitations of
this meta-analysis resulted from the variation in types of interventions and small sample size.
A 2019 Hayes health technology assessment, updated in 2022 regarding epidural steroid injections for cervical
radiculopathy concluded that the evidence did not demonstrate any beneficial effect of ESIs on pain or disability
associated with cervical radiculopathy compared with epidural injection of anesthetic alone. Although complications
reported in the reviewed studies were generally mild and transient, serious AEs have occurred, including paraplegia,
meningitis, and epidural abscess. Differences, often subtle, in the injection route, region, steroid, anesthetic, and patient
pathology result in a vast array of procedural options for ESI, and such variability makes interpretation of existing ESI data
difficult.
Smith et al (2019) published the results of a systematic review of 19 studies assessing the efficacy of lumbar
transforaminal steroid injection for radicular pain due to lumbar disc herniation. Placebo controlled RCTs, pragmatic
studies, and observational studies were included in the analysis. Utilizing a threshold of ≥ 50% reduction in pain,
treatment success rates across studies were 63% (Range: 58 to 68%) at 1-month, 74% (Range: 68-80%) at 3-months,
64% (59-69%) at 6-months, and 64% (57-71%) at 1year. The authors concluded that there is strong evidence that lumbar
transforaminal injection of steroids is an effective treatment for radicular pain due to disc herniation.